Tetanus Clinical Trial
Official title:
A Phase III, Observer-blinded Randomised, Multi-centre Clinical Study of the Safety, Immunogenicity and Consistency of Three Manufacturing Lots of GSK Biologicals' Candidate Tdap Vaccine as Compared to a US-licensed Td Vaccine When Given as a Booster Dose to Healthy Adolescents (10-18 Years of Age)
| Verified date | September 2016 |
| Source | GlaxoSmithKline |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).
| Status | Completed |
| Enrollment | 4116 |
| Est. completion date | April 2004 |
| Est. primary completion date | April 2004 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 10 Years to 18 Years |
| Eligibility |
Inclusion Criteria: - Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP). Exclusion Criteria: - Use of any other investigational drug or vaccine 30 days preceding study vaccination. - Chronic administration of immunosuppressants. - Administration of pre-school DTP vaccine within previous 5 years. - Administration of Td booster within previous 10 years. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| United States | GSK Investigational Site | Akron | Ohio |
| United States | GSK Investigational Site | Bardstown | Kentucky |
| United States | GSK Investigational Site | Boston | Massachusetts |
| United States | GSK Investigational Site | Boston | Massachusetts |
| United States | GSK Investigational Site | Boulder | Colorado |
| United States | GSK Investigational Site | Bryan | Texas |
| United States | GSK Investigational Site | Centennial | Colorado |
| United States | GSK Investigational Site | Chapel Hill | North Carolina |
| United States | GSK Investigational Site | Chicago | Illinois |
| United States | GSK Investigational Site | Cleveland | Ohio |
| United States | GSK Investigational Site | Durham | North Carolina |
| United States | GSK Investigational Site | Escondido | California |
| United States | GSK Investigational Site | Fullerton | California |
| United States | GSK Investigational Site | Georgetown | Texas |
| United States | GSK Investigational Site | Golden | Colorado |
| United States | GSK Investigational Site | Houston | Texas |
| United States | GSK Investigational Site | Jacksonville | Florida |
| United States | GSK Investigational Site | Jonesboro | Arkansas |
| United States | GSK Investigational Site | Kingsport | Tennessee |
| United States | GSK Investigational Site | Little Rock | Arkansas |
| United States | GSK Investigational Site | Lumberton | North Carolina |
| United States | GSK Investigational Site | Mesa | Arizona |
| United States | GSK Investigational Site | Middletown | Connecticut |
| United States | GSK Investigational Site | Milford | Massachusetts |
| United States | GSK Investigational Site | New Bedford | Maine |
| United States | GSK Investigational Site | Norfolk | Virginia |
| United States | GSK Investigational Site | Norwich | Connecticut |
| United States | GSK Investigational Site | Omaha | Nebraska |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Pittsburgh | Pennsylvania |
| United States | GSK Investigational Site | Redondo Beach | California |
| United States | GSK Investigational Site | Rochester | New York |
| United States | GSK Investigational Site | Rolling Hills Est | California |
| United States | GSK Investigational Site | Salt Lake City | Utah |
| United States | GSK Investigational Site | Sellersville | Pennsylvania |
| United States | GSK Investigational Site | Stony Brook | New York |
| United States | GSK Investigational Site | Tempe | Arizona |
| United States | GSK Investigational Site | Temple | Texas |
| United States | GSK Investigational Site | Torrance | California |
| United States | GSK Investigational Site | University Heights | Ohio |
| United States | GSK Investigational Site | West Jordan | Utah |
| United States | GSK Investigational Site | Whitehouse Station | New Jersey |
| United States | GSK Investigational Site | Woburn | Massachusetts |
| United States | GSK Investigational Site | Yorba Linda | California |
| Lead Sponsor | Collaborator |
|---|---|
| GlaxoSmithKline |
United States,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00352963 -
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).
|
Phase 3 | |
| Not yet recruiting |
NCT04056728 -
A Phase IV Study to Assess the Safety of EupentaTM Inj
|
Phase 4 | |
| Completed |
NCT00753649 -
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants
|
Phase 4 | |
| Completed |
NCT02538211 -
The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses
|
N/A | |
| Completed |
NCT01917357 -
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject
|
Phase 3 | |
| Completed |
NCT01689324 -
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents
|
Phase 1/Phase 2 | |
| Completed |
NCT01444781 -
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
|
Phase 3 | |
| Completed |
NCT01214889 -
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.
|
Phase 3 | |
| Completed |
NCT00804284 -
Database Surveillance Safety Study of PENTACEL® Vaccine
|
N/A | |
| Completed |
NCT00534833 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™
|
Phase 3 | |
| Completed |
NCT00514709 -
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infants
|
Phase 3 | |
| Completed |
NCT00379977 -
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
|
Phase 3 | |
| Completed |
NCT00772369 -
Retrospective Survey of Safety of Fourth Dose Pentacel® in Children
|
Phase 4 | |
| Completed |
NCT00879827 -
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
|
Phase 3 | |
| Completed |
NCT01457495 -
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly
|
Phase 2 | |
| Completed |
NCT01267058 -
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT02853929 -
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
|
Phase 4 | |
| Completed |
NCT02858440 -
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
|
Phase 3 | |
| Recruiting |
NCT06049940 -
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
|
Phase 3 | |
| Completed |
NCT00385255 -
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
|
Phase 3 |